Search
nipocalimab-aahu (Imaavy)
Indications:
- treatment of myasthenia gravis with with anti-AChR Ab or anti-MuSK Ab [1,2]
Dosage:
- 30 mg/kg loading dose, then 15 mg/kg every 2 weeks
Adverse effects:
- headache (14.3%)
- muscle spasms (12.2%)
- COVID-19 (15.3%)
- peripheral edema (11.2%)
Mechanism of action:
- blocks IgG binding site on the neonatal Fc receptor
- reduces serum IgG (total), including pathogenic IgG autoantibodies in generalized myasthenia gravis [1]
General
neurologic agent
References
- George J
Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis.
Phase III trial met primary endpoint at 6 months.
MedPage Today October 16, 2024
https://www.medpagetoday.com/meetingcoverage/aanem/112433
- George J
FDA Approves Nipocalimab for Adult and Pediatric Myasthenia Gravis.
FcRn blocker gets green light for patients with anti-AChR or anti-MuSK antibodies.
MedPage Today April 30, 2025
https://www.medpagetoday.com/neurology/generalneurology/115356